Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)

NCT00954278 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT00954278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00954278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1
Overall status
Completed
Start date
July 28, 2009
Completion date
December 23, 2015
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung